Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer

Kobayashi, Kokoro; Ito, Yoshiaki; Matsuura, M.; Fukada, Ippei; Horii, Rie; Takahashi, Shunji; Akiyama, Futoshi; Iwase, Takuji; Hozumi, Yasuo; Yasuda, Yoshikazu; Hatake, Kiyohiko

doi:10.1007/s00595-015-1252-x

Cited by 39 publications

(37 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although treatable, MBC remains an incurable disease with a median overall survival of ∼2–3 years and a 5-year survival of only ∼25% [2–4]. Some more recent series seem to indicate an improvement in median overall survival [5, 6]. …”

Section: Introductionmentioning

confidence: 99%

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

Cardoso¹,

et al. 2017

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

Cardoso¹,

et al. 2017

View full text Add to dashboard Cite

“…However, few studies have examined the relationship between intrinsic subtypes and the PRS of patients with recurrent breast cancer [ 11 – 14 ] . This study aimed to evaluate the clinicopathological features and PRS according to intrinsic molecular subtypes of breast cancer in patients treated with NAC and subsequent curative surgery.…”

Section: Introductionmentioning

confidence: 99%

Significance of intrinsic breast cancer subtypes on the long-term prognosis after neoadjuvant chemotherapy

et al. 2018

View full text Add to dashboard Cite

BackgroundThe prognosis of breast cancer and the treatment response to neoadjuvant chemotherapy (NAC) differ depending on the intrinsic molecular subtypes. We evaluated the prognostic significance of immunohistological subtypes in patients with recurrent breast cancer after treatment with NAC and surgery.MethodsA total of 237 patients with breast cancer treated with NAC and subsequent curative surgery between 2007 and 2015 were analyzed. The correlation between intrinsic molecular subtypes and clinicopathological features, prognosis, and pathological complete response (pCR) rate of NAC were investigated retrospectively.ResultsThere were 55 (23.2%) patients with recurrence after surgery. No significant difference in post-recurrence survival (PRS) was noted among the subtypes (p = 0.397). In patients with estrogen receptor-positive human epidermal growth factor receptor (HER) 2-negative (luminal) malignancy, PRS was significantly better in the pCR group than in the non-pCR group (p = 0.031). Conversely, pCR was not a significant predictor of improved PRS in patients with triple-negative breast cancer (TNBC; p = 0.329). Multivariate analysis revealed that the efficacy of NAC [hazard ratio (HR) 300.204, p < 0.001] and the initial metastasis site (HR 15.037, p = 0.005) were independent predictors for PRS in patients with luminal breast cancer, while Ki-67 (HR 51.171, p = 0.020) and the initial metastasis site (HR 13.318, p = 0.048) were independent predictors for PRS in patients with TNBC.ConclusionsThe prognostic factors for each intrinsic subtype should be evaluated separately in patients with recurrent breast cancer following NAC and surgery.

show abstract

“…The etiology of this is unknown, but it may refer to the loss of expression of the cellcell adhesion molecule E-cadherin in invasive lobular carcinoma (18). A retrospective analysis from 2016 has reported a median survival time (MST) of 55.5 months for all MBC subtypes (59.9 months for the luminal one) with clear improvement in the recent years (2000-2008) in comparison to 1977-1989 (19). Some cases of luminal MBC (7.3-11.6%) have their first distant site of recurrence in the skin.…”

Section: Discussionmentioning

confidence: 99%

Long-Term Survival and Complete Response to Anastrozole in Breast Cancer Patient With Cutaneous Metastases Only

Sedloev¹,

Vlahova²,

Usheva³

et al. 2019

Anticancer Res

View full text Add to dashboard Cite

Background/Aim: Metastatic breast cancer (MBC) represents a wide spectrum of heterogeneous conditions with different secondary spread sites, time to relapse and biology. MBC is still considered an incurable disease despite the fact that survival rates have improved in the last years. Cutaneous metastases are a rare site for metastatic spread and indicate advanced disease. The aim of this study is to demonstrate the excellent therapeutic result following endocrine therapy only in MBC with just skin involvement. Case Report: We present a case of an 82-year-old woman with no family history of breast cancer (BC), who was diagnosed with de novo metastatic estrogen/progesterone receptor-positive and HER2-negative invasive lobular BC. The only site of secondary spread was the skin. She was treated with just endocrine therapy for 116 months with which she achieved and maintained long-term complete clinical response (CR). Discussion: To our knowledge this is the only case of lobular BC with de novo metastatic manifestation as multiple skin metastases, which achieved CR following the aromatase inhibitor treatment (anastrozole) with such impressive long-term overall survival. Breast cancer (BC) is the most common malignancy in women worldwide. Most patients diagnosed with early BC have a longterm survival, but despite optimal treatment, nearly 30% relapse 4393 This article is freely accessible online.

show abstract

Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer

Cited by 39 publications

References 30 publications

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

Significance of intrinsic breast cancer subtypes on the long-term prognosis after neoadjuvant chemotherapy

Long-Term Survival and Complete Response to Anastrozole in Breast Cancer Patient With Cutaneous Metastases Only

Contact Info

Product

Resources

About